TY - JOUR
T1 - Treatment de-escalation in HPV-positive oropharyngeal carcinoma
T2 - Ongoing trials, critical issues and perspectives
AU - Mirghani, H.
AU - Amen, F.
AU - Blanchard, P.
AU - Moreau, F.
AU - Guigay, J.
AU - Hartl, D. M.
AU - Lacau St Guily, J.
N1 - Publisher Copyright:
© 2014 UICC.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Due to the generally poor prognosis of head and neck squamous cell carcinoma (HNSCC), treatment has been intensified, these last decades, leading to an increase of serious side effects. High-risk human papillomavirus (HR-HPV) infection has been recently etiologically linked to a subset of oropharyngeal squamous cell carcinoma (OPSCC), which is on the increase. These tumors are different, at the clinical and molecular level, when compared to tumors caused by traditional risk factors. Additionally, their prognosis is much more favorable which has led the medical community to consider new treatment strategies. Indeed, it is possible that less intensive treatment regimens could achieve similar efficacy with less toxicity and improved quality of life. Several clinical trials, investigating different ways to de-escalate treatment, are currently ongoing. In this article, we review these main approaches, discuss the rationale behind them and the issues raised by treatment deescalation in HPV-positive OPSCC.
AB - Due to the generally poor prognosis of head and neck squamous cell carcinoma (HNSCC), treatment has been intensified, these last decades, leading to an increase of serious side effects. High-risk human papillomavirus (HR-HPV) infection has been recently etiologically linked to a subset of oropharyngeal squamous cell carcinoma (OPSCC), which is on the increase. These tumors are different, at the clinical and molecular level, when compared to tumors caused by traditional risk factors. Additionally, their prognosis is much more favorable which has led the medical community to consider new treatment strategies. Indeed, it is possible that less intensive treatment regimens could achieve similar efficacy with less toxicity and improved quality of life. Several clinical trials, investigating different ways to de-escalate treatment, are currently ongoing. In this article, we review these main approaches, discuss the rationale behind them and the issues raised by treatment deescalation in HPV-positive OPSCC.
KW - Human papillomavirus
KW - Oropharyngeal cancers
KW - PD-1:PD-L1 immune checkpoint
KW - PI3K pathway
KW - Treatment de-escalation
UR - http://www.scopus.com/inward/record.url?scp=84921000202&partnerID=8YFLogxK
U2 - 10.1002/ijc.28847
DO - 10.1002/ijc.28847
M3 - Short survey
C2 - 24622970
AN - SCOPUS:84921000202
SN - 0020-7136
VL - 136
SP - 1494
EP - 1503
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 7
ER -